AeroLeads people directory · profile
Michael Scholle Email & Phone Number
Operations Director-Site Head, Discovery
at
Tango Biosciences, Inc.
1 work email found
@tangobio.com
3 phones found area 312 and 650
LinkedIn matched
✓ Verified Jul 2026
4 data sources
Profile completeness 100%
Current company
Role
Operations Director-Site Head, Discovery
Location
Greater Chicago Area, United States
Company size
Who is Michael Scholle? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Michael Scholle is listed as Operations Director-Site Head, Discovery at Tango Biosciences, Inc., a with 6 employees, based in Greater Chicago Area, United States. AeroLeads shows a work email signal at tangobio.com, phone signal with area code 312, 650, and a matched LinkedIn profile for Michael Scholle.
Michael Scholle previously worked as Operations Director and Site Head at Charles River Laboratories and Member Board of Directors at Tango Biosciences. Michael Scholle holds M.B.A. from Roosevelt University.
Company email context
Email format at Tango Biosciences, Inc.
This section adds company-level context without repeating Michael Scholle's masked contact details.
{first_initial}{last}@tangobio.com
89% confidence
AeroLeads found 1 current-domain work email signal for Michael Scholle. Compare company email patterns before reaching out.
Profile bio
About Michael Scholle
Biochemist, technologist, entrepreneur and executive with experience in building biotech companies on both the technical and business sides. Innovating new technologies to enhance the discovery of new drugs for the treatment of human diseases. Key involvement in building, growing and exiting multiple biotechs (Versartis IPO in 2014, Amunix Pharmaceuticals $1.2B in 2022, SAMDI Tech $65M in 2023, and Tango Bio- current Board Member).Over 20 years of experience building and commercializing technology platforms in drug discovery, high throughput screening, MALDI TOF MS, Affinity Selection Mass Spectrometry (ASMS), label-free / fluorescence / radioactivity assays, biochemistry, affinity reagent generation, protein-protein interactions, phage display, protease substrate mapping, molecular biology, and microbial functional genomics. PI of Specialized Center for NCI NExT Program, SBIR Phase I/II grant awardee.
Listed skills include Biochemistry, Drug Discovery, Molecular Biology, High Throughput Screening, and 22 others.
Current workplace
Michael Scholle's current company
Company context helps verify the profile and gives searchers a useful next step.
Tango Biosciences, Inc.
11 roles
Michael Scholle work experience
A career timeline built from the work history available for this profile.
Operations Director And Site Head
CurrentOperations and site lead for the SAMDI business unit within Charles River-Chicago. Led integration of the SAMDI Tech acquisition into the Charles River Labs broader corporate portfolio, with continued double digit revenue growth during the integration. Lead dozens of small molecule discovery projects for biotech and pharma clients in multinational collaborative settings. Responsible for growth of the site and expansion of technical capabilities around mass spectrometry and beyond.
Jan 2023 - Present
Member Board Of Directors
Current
Tango Biosciences
Tango is an innovative phage display platform technology company that is transforming the landscape in antibody and antibody mimics for assay detection from research tools through diagnostics.
Jan 2018 - Present
Chief Operating Officer, Co-Founder
Jan 2019 - Jan 2023
Vice President Of Operations And Technology, Co-Founder
Co-founder of SAMDI Tech, acquired by Charles River Labs in 2023 for $65M. Built this profitable biotechnology company through a bootstrap model with no Founder or Venture funding. SAMDI Tech is a CRO that offers unique assay capabilities that are commercially available through a contract assay and drug discovery offering. The assay platform, SAMDI, combines mass spectrometry with surface chemistry and high-density arrays for rapid and quantitative measurement of analytes in biochemical reactions. Our approach to screening enzyme activities eliminates the caveats of labeled methodologies that include: reducing rates of false positives and negatives, shortening assay development times, and screening in a high-throughput format. SAMDI provides a better understanding of biological function and aids in the discovery of early stage enzyme modulators involved in human disease.
Jan 2016 - Dec 2018
Director Of Operations And Technology, Co-Founder
Co-founder of SAMDI Tech Inc. Oversees all business and scientific operations. Technical lead on over 70 target projects with 9 top 10 pharma and several small pharma/biotech clients. Projects range from enzyme kinetics through high throughput drug discovery, as well as hit follow up activities. Integral part of the SAMDI Tech business development team with over 200 technical presentations. Responsible for all accounting and financial functions. Manage a team of scientists that conducts mass spectrometry-based biochemical assays. PI on SBIR Phase I and II grants totaling over $800k.
Jan 2011 - Dec 2015
Member Board Of Directors
Amunix
Amunix Pharmaceuticals, acquired in 2022 by Sanofi for $1.2B, is an industry leader in the discovery and development of long-acting protein-based therapeutics and drug conjugation technologies. Amunix’ pipeline products are based on its proprietary XTEN® half-life extension, XDC drug-conjugate delivery and ProTIA pro-drug, bispecific T-cell engager platform technologies. Amunix is applying these advances in delivery technology over a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing. The company is actively engaged in both a diverse array of internal product development efforts as well as ongoing collaborations with partnering companies.
Apr 2017 - May 2018
Commercialization Professional
Lead scientist in the development and commercialization of SAMDI, a label-free drug discovery platform for high throughput screening of biochemical assays. Integration of liquid handling processes to high density biochip arrays. Label-free assay development and enzyme substrate optimization for discovery of small molecule inhibitors. Secured non-dilutive funding to initiate a spin-out company.
Jul 2009 - Aug 2011
Scientist And Operations Manager
Amunix Pharmaceuticals Inc
Founding Scientist and Lead Molecular Biologist on several projects to extend half-life of existing biologics in blood using the revolutionary XTEN technology. Responsible for general business operations and management of personnel. Part of the Amunix team that licensed XTEN to a spin off, Versartis, which exited with an IPO in March 2014. Amunix was acquired in 2022 by Sanofi for $1.2B.
Jan 2006 - Jul 2009
Senior Research Associate
Lead phage display scientist and molecular biologist on several projects for the development of antibodies and affinity reagents. Developed cutting-edge phage display libraries and procedures for discovery of novel peptide ligands.
Apr 2002 - Jan 2006
Advanced Research Associate
Scientific lead on pioneering whole-genome determination of essential genes in E. coli using transposon mutagenesis and PCR mapping. Identified several gene products as antimicrobial drug targets. Led several projects for characterizing synthesis of CoA, riboflavin, NAD, and isoprenoids.
Jan 2001 - Apr 2002
3 education records
Michael Scholle education
M.B.A.
Roosevelt University
M.S., Molecular Microbiology
Northern Illinois University
B.S., Biology
Northern Illinois University
FAQ
Frequently asked questions about Michael Scholle
Quick answers generated from the profile data available on this page.
What company does Michael Scholle work for?
Michael Scholle works for Tango Biosciences, Inc..
What is Michael Scholle's role at Tango Biosciences, Inc.?
Michael Scholle is listed as Operations Director-Site Head, Discovery at Tango Biosciences, Inc..
What is Michael Scholle's email address?
AeroLeads has found 1 work email signal at @tangobio.com for Michael Scholle at Tango Biosciences, Inc..
What is Michael Scholle's phone number?
AeroLeads has found 3 phone signal(s) with area code 312, 650 for Michael Scholle at Tango Biosciences, Inc..
Where is Michael Scholle based?
Michael Scholle is based in Greater Chicago Area, United States while working with Tango Biosciences, Inc..
What companies has Michael Scholle worked for?
Michael Scholle has worked for Tango Biosciences, Inc., Charles River Laboratories, Tango Biosciences, Samdi Tech Inc, and Amunix.
How can I contact Michael Scholle?
You can use AeroLeads to view verified contact signals for Michael Scholle at Tango Biosciences, Inc., including work email, phone, and LinkedIn data when available.
What schools did Michael Scholle attend?
Michael Scholle holds M.B.A. from Roosevelt University.
What skills is Michael Scholle known for?
Michael Scholle is listed with skills including Biochemistry, Drug Discovery, Molecular Biology, High Throughput Screening, Biotechnology, Mass Spectrometry, Assay Development, and Enzyme Assays.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial